Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (L... by Margolis, David A, Dr, Brinson, Cynthia C, MD, Smith, Graham H R, MD, de Vente, Jerome, MD, Hagins, Debbie P, MD, Eron, Joseph J, Prof, Griffith, Sandy K, PharmD, Clair, Marty H St, BS, Stevens, Marita C, MD, Williams, Peter E, PhD, Ford, Susan L, PharmD, Stancil, Britt S, BS, Bomar, Melinda M, BS, Hudson, Krischan J, PhD, Smith, Kimberly Y, MD, Spreen, William R, PharmD

Get full text

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING... by Cahn, Pedro, Dr, Pozniak, Anton L, MD, Mingrone, Horacio, MD, Shuldyakov, Andrey, MD, Brites, Carlos, MD, Andrade-Villanueva, Jaime F, MD, Richmond, Gary, MD, Buendia, Carlos Beltran, MD, Fourie, Jan, MD, Ramgopal, Moti, MD, Hagins, Debbie, MD, Felizarta, Franco, MD, Madruga, Jose, MD, Reuter, Tania, MD, Newman, Tamara, MD, Small, Catherine B, MD, Lombaard, John, MD, Grinsztejn, Beatriz, MD, Dorey, David, MMath, Underwood, Mark, PhD, Griffith, Sandy, PharmD, Min, Sherene, MD

Get full text